Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
'We are pleased to welcome Dr. Jain to Avalo's Board of Directors,' said Michael Heffernan, Chairman of the Board. 'Rita's extensive experience spanning clinical development, regulatory strategy, and executive leadership at multiple development-stage biopharma companies will be invaluable as we continue to advance AVTX-009, a high affinity anti-IL-1β monoclonal antibody in a Phase 2 trial for hidradenitis suppurativa (HS) and take a thoughtful, capital-efficient approach to our broader development strategy.'
'I am excited to join Avalo's Board at this pivotal stage in the company's growth, with the progressing Phase 2 LOTUS trial in HS expected to readout in the middle of next year,' said Dr. Jain. 'I was drawn to this opportunity given AVTX-009's proven mechanism of action, its potential to become a best-in-disease treatment in HS, and its potential in addressing unmet needs in a number of additional large inflammatory diseases. With my experience in navigating strategic growth in immunology and inflammation across multiple indications and stages of development, I look forward to supporting the leadership team and collaborating with my fellow Board members as Avalo works to bring potential best in disease treatments to patients in need.'
Dr. Jain is a Rheumatologist who brings over two decades of leadership experience in biopharmaceutical development, clinical strategy, and regulatory affairs across multiple therapeutic areas, including immunology, inflammation, nephrology, and rare diseases. She most recently served as Executive Vice President and Chief Medical Officer at ChemoCentryx, where she advanced development and supported commercialization of Tavneos® (avacopan), a first-in-class treatment for ANCA-associated vasculitis, and supported the company's acquisition by Amgen in 2022. Prior to that, she was Senior Vice President and Chief Medical Officer at Akebia Therapeutics. Additionally, Dr. Jain held key leadership positions at AbbVie, Pfizer, and Immunovant, overseeing global development programs, regulatory interactions, and clinical operations for multiple therapeutic candidates. She also serves on the boards of Celldex Therapeutics and AnaptysBio. Dr. Jain received her M.D. from the State University of New York at Stony Brook School of Medicine and completed her residency in internal medicine at Staten Island University Hospital, followed by a fellowship in rheumatology at North Shore University Hospital and a Clinical Research Fellowship at the University of Texas Southwestern Medical Center, Dallas.
About Avalo Therapeutics
Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. For more information about Avalo, please visit www.avalotx.com.
About AVTX-009
AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology.
Forward-Looking StatementsThis press release may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond Avalo's control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation, statements with respect to Avalo's plans, objectives, projections, expectations and intentions and other statements identified by words such as 'projects,' 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'continue,' 'seeks,' 'aims,' 'predicts,' 'believes,' 'expects,' 'anticipates,' 'estimates,' 'intends,' 'plans,' 'potential,' or similar expressions (including their use in the negative), or by discussions of future matters such as: drug development costs, timing of trials and trial results, and other risks including reliance on investigators and enrollment of patients in clinical trials; reliance on key personnel; regulatory risks; general economic and market risks and uncertainties, including those caused by the war in Ukraine and the Middle East; and those other risks detailed in Avalo's filings with the Securities and Exchange Commission, available at www.sec.gov. Actual results may differ from those set forth in the forward-looking statements. Except as required by applicable law, Avalo expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Avalo's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
For media and investor inquiriesChristopher Sullivan, CFO Avalo Therapeutics, Inc. ir@avalotx.com 410-803-6793
or
Meru AdvisorsLauren Glaserlglaser@meruadvisors.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
Bentley Earnings: What To Look For From BSY
Infrastructure design software provider Bentley Systems (NASDAQ:BSY) will be reporting results this Wednesday morning. Here's what investors should know. Bentley beat analysts' revenue expectations by 1.4% last quarter, reporting revenues of $370.5 million, up 9.7% year on year. It was a very strong quarter for the company, with a solid beat of analysts' EBITDA estimates and an impressive beat of analysts' billings estimates. Is Bentley a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Bentley's revenue to grow 10% year on year to $363.4 million, slowing from the 11.3% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.29 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Bentley has missed Wall Street's revenue estimates four times over the last two years. Looking at Bentley's peers in the software-as-a-service segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Manhattan Associates delivered year-on-year revenue growth of 2.7%, beating analysts' expectations by 3.3%, and Palantir reported revenues up 48%, topping estimates by 6.8%. Manhattan Associates traded up 7% following the results. Read our full analysis of Manhattan Associates's results here and Palantir's results here. Debates around the economy's health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the software-as-a-service stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3% on average over the last month. Bentley is up 4.3% during the same time and is heading into earnings with an average analyst price target of $54.31 (compared to the current share price of $57.90). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 minutes ago
- Yahoo
Noodles (NDLS) To Report Earnings Tomorrow: Here Is What To Expect
Casual restaurant chain Noodles & Company (NASDAQ:NDLS) will be announcing earnings results this Wednesday afternoon. Here's what to expect. Noodles met analysts' revenue expectations last quarter, reporting revenues of $123.8 million, up 2% year on year. It was a slower quarter for the company, with a significant miss of analysts' EBITDA estimates and a significant miss of analysts' EPS estimates. Is Noodles a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Noodles's revenue to grow 3.5% year on year to $131.9 million, improving from the 1.8% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.06 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Noodles has missed Wall Street's revenue estimates six times over the last two years. Looking at Noodles's peers in the modern fast food segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Shake Shack delivered year-on-year revenue growth of 12.6%, beating analysts' expectations by 0.9%, and Wingstop reported revenues up 12%, topping estimates by 0.5%. Shake Shack traded down 20.7% following the results while Wingstop was up 29.7%. Read our full analysis of Shake Shack's results here and Wingstop's results here. Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the modern fast food stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 6.3% on average over the last month. Noodles is up 14% during the same time and is heading into earnings with an average analyst price target of $2.83 (compared to the current share price of $0.90). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
33 minutes ago
- Yahoo
Earnings To Watch: Allient (ALNT) Reports Q2 Results Tomorrow
Precision motion systems specialist Allient (NASDAQ:ALNT) will be reporting results this Wednesday afternoon. Here's what to expect. Allient beat analysts' revenue expectations by 5.7% last quarter, reporting revenues of $132.8 million, down 9.5% year on year. It was an incredible quarter for the company, with a solid beat of analysts' EPS estimates and an impressive beat of analysts' EBITDA estimates. Is Allient a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Allient's revenue to decline 2.3% year on year to $132.9 million, improving from the 7.3% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.47 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Allient has missed Wall Street's revenue estimates twice over the last two years. Looking at Allient's peers in the electronic components segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Bel Fuse delivered year-on-year revenue growth of 26.3%, beating analysts' expectations by 10.1%, and Littelfuse reported revenues up 9.8%, topping estimates by 6.8%. Bel Fuse traded up 18.8% following the results while Littelfuse was also up 9.1%. Read our full analysis of Bel Fuse's results here and Littelfuse's results here. Investors in the electronic components segment have had steady hands going into earnings, with share prices up 1.4% on average over the last month. Allient is up 4.7% during the same time and is heading into earnings with an average analyst price target of $37.33 (compared to the current share price of $39.67). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
